Generation Scotland: the Scottish Family Health Study - a new resource for researching genes and heritability

Blair H Smith; Harry Campbell; Douglas Blackwood; John Connell; Mike Connor; Ian J Deary; Anna F Dominiczak; Bridie Fitzpatrick; Ian Ford; Cathy Jackson; Gillian Haddow; Shona Kerr; Robert Lindsay; Mark McGilchrist; Robin Morton; Graeme Murray; Colin N A Palmer; Jill P Pell; Stuart H Ralston; David St Clair; Frank Sullivan; Graham Watt; Roland Wolf; Alan Wright; David Porteous; Andrew D Morris

doi:10.1186/1471-2350-7-74

Generation Scotland: the Scottish Family Health Study - a new resource for researching genes and heritability

Blair H Smith, Harry Campbell, Douglas Blackwood, John Connell, Mike Connor, Ian J Deary, Anna F Dominiczak, Bridie Fitzpatrick, Ian Ford, Cathy Jackson, Gillian Haddow, Shona Kerr, Robert Lindsay, Mark McGilchrist, Robin Morton, Graeme Murray, Colin N A Palmer, Jill P Pell, Stuart H Ralston, David St ClairFrank Sullivan, Graham Watt, Roland Wolf, Alan Wright, David Porteous, Andrew D Morris

Research output: Contribution to journal › Article › peer-review

170 Citations (Scopus)

7 Downloads (Pure)

Abstract

Background: Generation Scotland: the Scottish Family Health Study aims to identify genetic variants accounting for variation in levels of quantitative traits underlying the major common complex diseases (such as cardiovascular disease, cognitive decline, mental illness) in Scotland.

Methods/Design: Generation Scotland will recruit a family-based cohort of up to 50,000 individuals (comprising siblings and parent-offspring groups) across Scotland. It will be a six-year programme, beginning in Glasgow and Tayside in the first two years (Phase 1) before extending to other parts of Scotland in the remaining four years (Phase 2). In Phase 1, individuals aged between 35 and 55 years, living in the East and West of Scotland will be invited to participate, along with at least one (and preferably more) siblings and any other first degree relatives aged 18 or over. The total initial sample size will be 15,000 and it is planned that this will increase to 50,000 in Phase 2. All participants will be asked to contribute blood samples from which DNA will be extracted and stored for future investigation. The information from the DNA, along with answers to a life-style and medical history questionnaire, clinical and biochemical measurements taken at the time of donation, and subsequent health developments over the life course (traced through electronic health records) will be stored and used for research purposes. In addition, a detailed public consultation process will begin that will allow respondents' views to shape and develop the study. This is an important aspect to the research, and forms the continuation of a long-term parallel engagement process.

Discussion: As well as gene identification, the family-based study design will allow measurement of the heritability and familial aggregation of relevant quantitative traits, and the study of how genetic effects may vary by parent-of-origin. Long-term potential outcomes of this research include the targeting of disease prevention and treatment, and the development of screening tools based on the new genetic information. This study approach is complementary to other population-based genetic epidemiology studies, such as UK Biobank, which are established primarily to characterise genes and genetic risk in the population.

Original language	English
Article number	74
Number of pages	9
Journal	BMC Medical Genetics
Volume	7
DOIs	https://doi.org/10.1186/1471-2350-7-74
Publication status	Published - 2 Oct 2006

Keywords

human-genome
primary-care
epidemiology
sequence
project

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1471-2350-7-74

Generation Scotland
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 264 KB

http://www.biomedcentral.com/1471-2350/7/74

Cite this

Smith, B. H., Campbell, H., Blackwood, D., Connell, J., Connor, M., Deary, I. J., Dominiczak, A. F., Fitzpatrick, B., Ford, I., Jackson, C., Haddow, G., Kerr, S., Lindsay, R., McGilchrist, M., Morton, R., Murray, G., Palmer, C. N. A., Pell, J. P., Ralston, S. H., ... Morris, A. D. (2006). Generation Scotland: the Scottish Family Health Study - a new resource for researching genes and heritability. BMC Medical Genetics, 7, Article 74. https://doi.org/10.1186/1471-2350-7-74

Smith, BH, Campbell, H, Blackwood, D, Connell, J, Connor, M, Deary, IJ, Dominiczak, AF, Fitzpatrick, B, Ford, I, Jackson, C, Haddow, G, Kerr, S, Lindsay, R, McGilchrist, M, Morton, R, Murray, G, Palmer, CNA, Pell, JP, Ralston, SH, St Clair, D, Sullivan, F, Watt, G, Wolf, R, Wright, A, Porteous, D & Morris, AD 2006, 'Generation Scotland: the Scottish Family Health Study - a new resource for researching genes and heritability', BMC Medical Genetics, vol. 7, 74. https://doi.org/10.1186/1471-2350-7-74

@article{2f83d58d04104f5889176d4543eaa008,

title = "Generation Scotland: the Scottish Family Health Study - a new resource for researching genes and heritability",

abstract = "Background: Generation Scotland: the Scottish Family Health Study aims to identify genetic variants accounting for variation in levels of quantitative traits underlying the major common complex diseases (such as cardiovascular disease, cognitive decline, mental illness) in Scotland.Methods/Design: Generation Scotland will recruit a family-based cohort of up to 50,000 individuals (comprising siblings and parent-offspring groups) across Scotland. It will be a six-year programme, beginning in Glasgow and Tayside in the first two years (Phase 1) before extending to other parts of Scotland in the remaining four years (Phase 2). In Phase 1, individuals aged between 35 and 55 years, living in the East and West of Scotland will be invited to participate, along with at least one (and preferably more) siblings and any other first degree relatives aged 18 or over. The total initial sample size will be 15,000 and it is planned that this will increase to 50,000 in Phase 2. All participants will be asked to contribute blood samples from which DNA will be extracted and stored for future investigation. The information from the DNA, along with answers to a life-style and medical history questionnaire, clinical and biochemical measurements taken at the time of donation, and subsequent health developments over the life course (traced through electronic health records) will be stored and used for research purposes. In addition, a detailed public consultation process will begin that will allow respondents' views to shape and develop the study. This is an important aspect to the research, and forms the continuation of a long-term parallel engagement process.Discussion: As well as gene identification, the family-based study design will allow measurement of the heritability and familial aggregation of relevant quantitative traits, and the study of how genetic effects may vary by parent-of-origin. Long-term potential outcomes of this research include the targeting of disease prevention and treatment, and the development of screening tools based on the new genetic information. This study approach is complementary to other population-based genetic epidemiology studies, such as UK Biobank, which are established primarily to characterise genes and genetic risk in the population.",

keywords = "human-genome, primary-care, epidemiology, sequence, project",

author = "Smith, {Blair H} and Harry Campbell and Douglas Blackwood and John Connell and Mike Connor and Deary, {Ian J} and Dominiczak, {Anna F} and Bridie Fitzpatrick and Ian Ford and Cathy Jackson and Gillian Haddow and Shona Kerr and Robert Lindsay and Mark McGilchrist and Robin Morton and Graeme Murray and Palmer, {Colin N A} and Pell, {Jill P} and Ralston, {Stuart H} and {St Clair}, David and Frank Sullivan and Graham Watt and Roland Wolf and Alan Wright and David Porteous and Morris, {Andrew D}",

year = "2006",

month = oct,

day = "2",

doi = "10.1186/1471-2350-7-74",

language = "English",

volume = "7",

journal = "BMC Medical Genetics",

issn = "1471-2350",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Generation Scotland

T2 - the Scottish Family Health Study - a new resource for researching genes and heritability

AU - Smith, Blair H

AU - Campbell, Harry

AU - Blackwood, Douglas

AU - Connell, John

AU - Connor, Mike

AU - Deary, Ian J

AU - Dominiczak, Anna F

AU - Fitzpatrick, Bridie

AU - Ford, Ian

AU - Jackson, Cathy

AU - Haddow, Gillian

AU - Kerr, Shona

AU - Lindsay, Robert

AU - McGilchrist, Mark

AU - Morton, Robin

AU - Murray, Graeme

AU - Palmer, Colin N A

AU - Pell, Jill P

AU - Ralston, Stuart H

AU - St Clair, David

AU - Sullivan, Frank

AU - Watt, Graham

AU - Wolf, Roland

AU - Wright, Alan

AU - Porteous, David

AU - Morris, Andrew D

PY - 2006/10/2

Y1 - 2006/10/2

N2 - Background: Generation Scotland: the Scottish Family Health Study aims to identify genetic variants accounting for variation in levels of quantitative traits underlying the major common complex diseases (such as cardiovascular disease, cognitive decline, mental illness) in Scotland.Methods/Design: Generation Scotland will recruit a family-based cohort of up to 50,000 individuals (comprising siblings and parent-offspring groups) across Scotland. It will be a six-year programme, beginning in Glasgow and Tayside in the first two years (Phase 1) before extending to other parts of Scotland in the remaining four years (Phase 2). In Phase 1, individuals aged between 35 and 55 years, living in the East and West of Scotland will be invited to participate, along with at least one (and preferably more) siblings and any other first degree relatives aged 18 or over. The total initial sample size will be 15,000 and it is planned that this will increase to 50,000 in Phase 2. All participants will be asked to contribute blood samples from which DNA will be extracted and stored for future investigation. The information from the DNA, along with answers to a life-style and medical history questionnaire, clinical and biochemical measurements taken at the time of donation, and subsequent health developments over the life course (traced through electronic health records) will be stored and used for research purposes. In addition, a detailed public consultation process will begin that will allow respondents' views to shape and develop the study. This is an important aspect to the research, and forms the continuation of a long-term parallel engagement process.Discussion: As well as gene identification, the family-based study design will allow measurement of the heritability and familial aggregation of relevant quantitative traits, and the study of how genetic effects may vary by parent-of-origin. Long-term potential outcomes of this research include the targeting of disease prevention and treatment, and the development of screening tools based on the new genetic information. This study approach is complementary to other population-based genetic epidemiology studies, such as UK Biobank, which are established primarily to characterise genes and genetic risk in the population.

AB - Background: Generation Scotland: the Scottish Family Health Study aims to identify genetic variants accounting for variation in levels of quantitative traits underlying the major common complex diseases (such as cardiovascular disease, cognitive decline, mental illness) in Scotland.Methods/Design: Generation Scotland will recruit a family-based cohort of up to 50,000 individuals (comprising siblings and parent-offspring groups) across Scotland. It will be a six-year programme, beginning in Glasgow and Tayside in the first two years (Phase 1) before extending to other parts of Scotland in the remaining four years (Phase 2). In Phase 1, individuals aged between 35 and 55 years, living in the East and West of Scotland will be invited to participate, along with at least one (and preferably more) siblings and any other first degree relatives aged 18 or over. The total initial sample size will be 15,000 and it is planned that this will increase to 50,000 in Phase 2. All participants will be asked to contribute blood samples from which DNA will be extracted and stored for future investigation. The information from the DNA, along with answers to a life-style and medical history questionnaire, clinical and biochemical measurements taken at the time of donation, and subsequent health developments over the life course (traced through electronic health records) will be stored and used for research purposes. In addition, a detailed public consultation process will begin that will allow respondents' views to shape and develop the study. This is an important aspect to the research, and forms the continuation of a long-term parallel engagement process.Discussion: As well as gene identification, the family-based study design will allow measurement of the heritability and familial aggregation of relevant quantitative traits, and the study of how genetic effects may vary by parent-of-origin. Long-term potential outcomes of this research include the targeting of disease prevention and treatment, and the development of screening tools based on the new genetic information. This study approach is complementary to other population-based genetic epidemiology studies, such as UK Biobank, which are established primarily to characterise genes and genetic risk in the population.

KW - human-genome

KW - primary-care

KW - epidemiology

KW - sequence

KW - project

U2 - 10.1186/1471-2350-7-74

DO - 10.1186/1471-2350-7-74

M3 - Article

SN - 1471-2350

VL - 7

JO - BMC Medical Genetics

JF - BMC Medical Genetics

M1 - 74

ER -

Generation Scotland: the Scottish Family Health Study - a new resource for researching genes and heritability

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this